BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Maire F, Micard S, Hammel P, Voitot H, Lévy P, Cugnenc PH, Ruszniewski P, Puig PL. Differential diagnosis between chronic pancreatitis and pancreatic cancer: value of the detection of KRAS2 mutations in circulating DNA. Br J Cancer 2002;87:551-4. [PMID: 12189555 DOI: 10.1038/sj.bjc.6600475] [Cited by in Crossref: 92] [Cited by in F6Publishing: 83] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Tsang JC, Lo YM. Circulating nucleic acids in plasma/serum. Pathology 2007;39:197-207. [PMID: 17454749 DOI: 10.1080/00313020701230831] [Cited by in Crossref: 115] [Cited by in F6Publishing: 107] [Article Influence: 8.2] [Reference Citation Analysis]
2 Howell JA, Khan SA, Knapp S, Thursz MR, Sharma R. The clinical role of circulating free tumor DNA in gastrointestinal malignancy. Translational Research 2017;183:137-54. [DOI: 10.1016/j.trsl.2016.12.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
3 Takai E, Yachida S. Circulating tumor DNA as a liquid biopsy target for detection of pancreatic cancer. World J Gastroenterol 2016;22:8480-8. [PMID: 27784960 DOI: 10.3748/wjg.v22.i38.8480] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 21] [Article Influence: 6.8] [Reference Citation Analysis]
4 O'Neill RS, Stoita A. Biomarkers in the diagnosis of pancreatic cancer: Are we closer to finding the golden ticket? World J Gastroenterol 2021;27:4045-87. [PMID: 34326612 DOI: 10.3748/wjg.v27.i26.4045] [Reference Citation Analysis]
5 Fleischhacker M, Schmidt B. Circulating nucleic acids (CNAs) and cancer--a survey. Biochim Biophys Acta. 2007;1775:181-232. [PMID: 17137717 DOI: 10.1016/j.bbcan.2006.10.001] [Cited by in Crossref: 187] [Cited by in F6Publishing: 338] [Article Influence: 12.5] [Reference Citation Analysis]
6 Gall TM, Frampton AE, Krell J, Habib NA, Castellano L, Stebbing J, Jiao LR. Cell-free DNA for the detection of pancreatic, liver and upper gastrointestinal cancers: has progress been made? Future Oncol 2013;9:1861-9. [PMID: 24295416 DOI: 10.2217/fon.13.152] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
7 Tjensvoll K, Lapin M, Buhl T, Oltedal S, Steen-Ottosen Berry K, Gilje B, Søreide JA, Javle M, Nordgård O, Smaaland R. Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer. Mol Oncol 2016;10:635-43. [PMID: 26725968 DOI: 10.1016/j.molonc.2015.11.012] [Cited by in Crossref: 86] [Cited by in F6Publishing: 79] [Article Influence: 14.3] [Reference Citation Analysis]
8 Woo W, Carey ET, Choi M. Spotlight on liposomal irinotecan for metastatic pancreatic cancer: patient selection and perspectives. Onco Targets Ther 2019;12:1455-63. [PMID: 30863113 DOI: 10.2147/OTT.S167590] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
9 Brychta N, Krahn T, von Ahsen O. Detection of KRAS Mutations in Circulating Tumor DNA by Digital PCR in Early Stages of Pancreatic Cancer. Clin Chem 2016;62:1482-91. [PMID: 27591291 DOI: 10.1373/clinchem.2016.257469] [Cited by in Crossref: 61] [Cited by in F6Publishing: 49] [Article Influence: 12.2] [Reference Citation Analysis]
10 Gerstenmaier JF, Malone DE. Mass lesions in chronic pancreatitis: benign or malignant? An “evidence-based practice” approach. Abdom Imaging 2011;36:569-77. [DOI: 10.1007/s00261-010-9658-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
11 Jacobson RA, Munding E, Hayden DM, Levy M, Kuzel TM, Pappas SG, Masood A. Evolving Clinical Utility of Liquid Biopsy in Gastrointestinal Cancers. Cancers (Basel) 2019;11:E1164. [PMID: 31412682 DOI: 10.3390/cancers11081164] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
12 Creemers A, Krausz S, Strijker M, van der Wel MJ, Soer EC, Reinten RJ, Besselink MG, Wilmink JW, van de Vijver MJ, van Noesel CJM, Verheij J, Meijer SL, Dijk F, Bijlsma MF, van Oijen MGH, van Laarhoven HWM. Clinical value of ctDNA in upper-GI cancers: A systematic review and meta-analysis. Biochim Biophys Acta Rev Cancer. 2017;1868:394-403. [PMID: 28801248 DOI: 10.1016/j.bbcan.2017.08.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
13 Pessoa LS, Heringer M, Ferrer VP. ctDNA as a cancer biomarker: A broad overview. Crit Rev Oncol Hematol. 2020;155:103109. [PMID: 33049662 DOI: 10.1016/j.critrevonc.2020.103109] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
14 Merdrignac A, Sulpice L, Rayar M, Rohou T, Quéhen E, Zamreek A, Boudjema K, Meunier B. Pancreatic head cancer in patients with chronic pancreatitis. Hepatobiliary & Pancreatic Diseases International 2014;13:192-7. [DOI: 10.1016/s1499-3872(14)60030-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
15 Fang F, He X, Deng H, Chen Q, Lu J, Spraul M, Yu Y. Discrimination of metabolic profiles of pancreatic cancer from chronic pancreatitis by high-resolution magic angle spinning 1H nuclear magnetic resonance and principal components analysis. Cancer Sci. 2007;98:1678-1682. [PMID: 17727683 DOI: 10.1111/j.1349-7006.2007.00589.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 3.5] [Reference Citation Analysis]
16 Dhar P, Kalghatgi S, Saraf V. Pancreatic cancer in chronic pancreatitis. Indian J Surg Oncol 2015;6:57-62. [PMID: 25937765 DOI: 10.1007/s13193-014-0373-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
17 Zandvakili I, Lazaridis KN. Cell-free DNA testing: future applications in gastroenterology and hepatology. Therap Adv Gastroenterol 2019;12:1756284819841896. [PMID: 31019553 DOI: 10.1177/1756284819841896] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
18 Zhu Y, Zhang H, Chen N, Hao J, Jin H, Ma X. Diagnostic value of various liquid biopsy methods for pancreatic cancer: A systematic review and meta-analysis. Medicine (Baltimore). 2020;99:e18581. [PMID: 32011436 DOI: 10.1097/md.0000000000018581] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 14.0] [Reference Citation Analysis]
19 Kunovsky L, Tesarikova P, Kala Z, Kroupa R, Kysela P, Dolina J, Trna J. The Use of Biomarkers in Early Diagnostics of Pancreatic Cancer. Can J Gastroenterol Hepatol 2018;2018:5389820. [PMID: 30186820 DOI: 10.1155/2018/5389820] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
20 Marchese R, Muleti A, Brozzetti S, Gandini O, Brunetti E, French D. Low value of detection of KRAS2 mutations in circulating DNA to differentiate chronic pancreatitis to pancreatic cancer. Br J Cancer. 2004;90:2243. [PMID: 15150585 DOI: 10.1038/sj.bjc.6601854] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
21 Rashid S, Singh N, Gupta S, Rashid S, Nalika N, Sachdev V, Bal CS, Datta Gupta S, Chauhan SS, Saraya A. Progression of Chronic Pancreatitis to Pancreatic Cancer: Is There a Role of Gene Mutations as a Screening Tool? Pancreas. 2018;47:227-232. [PMID: 29303908 DOI: 10.1097/mpa.0000000000000975] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
22 Umans DS, Hoogenboom SA, Sissingh NJ, Lekkerkerker SJ, Verdonk RC, van Hooft JE. Pancreatitis and pancreatic cancer: A case of the chicken or the egg. World J Gastroenterol 2021;27:3148-57. [PMID: 34163103 DOI: 10.3748/wjg.v27.i23.3148] [Reference Citation Analysis]
23 Zhou B, Xu JW, Cheng YG, Gao JY, Hu SY, Wang L, Zhan HX. Early detection of pancreatic cancer: Where are we now and where are we going? Int J Cancer. 2017;141:231-241. [PMID: 28240774 DOI: 10.1002/ijc.30670] [Cited by in Crossref: 79] [Cited by in F6Publishing: 68] [Article Influence: 19.8] [Reference Citation Analysis]
24 Ma M, Zhu H, Zhang C, Sun X, Gao X, Chen G. "Liquid biopsy"-ctDNA detection with great potential and challenges. Ann Transl Med 2015;3:235. [PMID: 26539452 DOI: 10.3978/j.issn.2305-5839.2015.09.29] [Cited by in F6Publishing: 41] [Reference Citation Analysis]
25 Marchese R, Muleti A, Pasqualetti P, Bucci B, Stigliano A, Brunetti E, De Angelis M, Mazzoni G, Tocchi A, Brozzetti S. Low correspondence between K-ras mutations in pancreatic cancer tissue and detection of K-ras mutations in circulating DNA. Pancreas. 2006;32:171-177. [PMID: 16552337 DOI: 10.1097/01.mpa.0000202938.63084.e3] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 2.5] [Reference Citation Analysis]
26 Rice A, Del Rio Hernandez A. The Mutational Landscape of Pancreatic and Liver Cancers, as Represented by Circulating Tumor DNA. Front Oncol 2019;9:952. [PMID: 31608239 DOI: 10.3389/fonc.2019.00952] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
27 Adamo P, Cowley CM, Neal CP, Mistry V, Page K, Dennison AR, Isherwood J, Hastings R, Luo J, Moore DA, Howard PJ, Miguel ML, Pritchard C, Manson M, Shaw JA. Profiling tumour heterogeneity through circulating tumour DNA in patients with pancreatic cancer. Oncotarget 2017;8:87221-33. [PMID: 29152076 DOI: 10.18632/oncotarget.20250] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
28 Gall TMH, Belete S, Khanderia E, Frampton AE, Jiao LR. Circulating Tumor Cells and Cell-Free DNA in Pancreatic Ductal Adenocarcinoma. Am J Pathol 2019;189:71-81. [PMID: 30558725 DOI: 10.1016/j.ajpath.2018.03.020] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 14.5] [Reference Citation Analysis]
29 Le Calvez-Kelm F, Foll M, Wozniak MB, Delhomme TM, Durand G, Chopard P, Pertesi M, Fabianova E, Adamcakova Z, Holcatova I. KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control. Oncotarget. 2016;7:78827-78840. [PMID: 27705932 DOI: 10.18632/oncotarget.12386] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 15.0] [Reference Citation Analysis]
30 Bernard V, Kim DU, San Lucas FA, Castillo J, Allenson K, Mulu FC, Stephens BM, Huang J, Semaan A, Guerrero PA, Kamyabi N, Zhao J, Hurd MW, Koay EJ, Taniguchi CM, Herman JM, Javle M, Wolff R, Katz M, Varadhachary G, Maitra A, Alvarez HA. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer. Gastroenterology 2019;156:108-118.e4. [PMID: 30240661 DOI: 10.1053/j.gastro.2018.09.022] [Cited by in Crossref: 113] [Cited by in F6Publishing: 100] [Article Influence: 37.7] [Reference Citation Analysis]
31 Turrini O, Cano C, Legoffic A, Delpero J, Dagorn J, Iovanna J. Genetic alterations in precancerous pancreatic lesions and their clinical implications. Gastroentérologie Clinique et Biologique 2009;33:1028-35. [DOI: 10.1016/j.gcb.2009.08.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
32 Su SB, Qin SY, Chen W, Luo W, Jiang HX. Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis. World J Gastroenterol 2015;21:4323-33. [PMID: 25892884 DOI: 10.3748/wjg.v21.i14.4323] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 18] [Article Influence: 4.6] [Reference Citation Analysis]
33 Wan J, Li H, Li Y, Zhu ML, Zhao P. Loss of heterozygosity of Kras2 gene on 12p12-13 in Chinese colon carcinoma patients. World J Gastroenterol. 2006;12:1033-1037. [PMID: 16534842 DOI: 10.3748/wjg.v12.i7.1037] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
34 Franczak C, Filhine-Tressarieu P, Broséus J, Gilson P, Merlin JL, Harlé A. Clinical Interest of Circulating Tumor DNA in Oncology. Arch Med Res 2018;49:297-305. [PMID: 30414710 DOI: 10.1016/j.arcmed.2018.10.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
35 Shaw TJ, Senterman MK, Dawson K, Crane CA, Vanderhyden BC. Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol Ther 2004;10:1032-42. [PMID: 15564135 DOI: 10.1016/j.ymthe.2004.08.013] [Cited by in Crossref: 183] [Cited by in F6Publishing: 174] [Article Influence: 11.4] [Reference Citation Analysis]
36 Giovinazzo F, Turri G, Zanini S, Butturini G, Scarpa A, Bassi C. Clinical implications of biological markers in Pancreatic Ductal Adenocarcinoma. Surg Oncol. 2012;21:e171-e182. [PMID: 22981281 DOI: 10.1016/j.suronc.2012.07.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
37 Däbritz J, Preston R, Hänfler J, Oettle H. Follow-up study of K-ras mutations in the plasma of patients with pancreatic cancer: correlation with clinical features and carbohydrate antigen 19-9. Pancreas. 2009;38:534-541. [PMID: 19295453 DOI: 10.1097/mpa.0b013e31819f6376] [Cited by in Crossref: 38] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
38 Satoh K. Molecular Approaches Using Body Fluid for the Early Detection of Pancreatic Cancer.Diagnostics (Basel). 2021;11. [PMID: 33671729 DOI: 10.3390/diagnostics11020375] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
39 Faria G, Silva E, Da Fonseca C, Quirico-Santos T. Circulating Cell-Free DNA as a Prognostic and Molecular Marker for Patients with Brain Tumors under Perillyl Alcohol-Based Therapy. Int J Mol Sci 2018;19:E1610. [PMID: 29848970 DOI: 10.3390/ijms19061610] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
40 Kong X, Sun T, Kong F, Du Y, Li Z. Chronic Pancreatitis and Pancreatic Cancer. Gastrointest Tumors. 2014;1:123-134. [PMID: 26674754 DOI: 10.1159/000365306] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
41 Hanash SM, Baik CS, Kallioniemi O. Emerging molecular biomarkers--blood-based strategies to detect and monitor cancer. Nat Rev Clin Oncol. 2011;8:142-150. [PMID: 21364687 DOI: 10.1038/nrclinonc.2010.220] [Cited by in Crossref: 209] [Cited by in F6Publishing: 186] [Article Influence: 20.9] [Reference Citation Analysis]
42 Yadav DK, Bai X, Yadav RK, Singh A, Li G, Ma T, Chen W, Liang T. Liquid biopsy in pancreatic cancer: the beginning of a new era. Oncotarget 2018;9:26900-33. [PMID: 29928492 DOI: 10.18632/oncotarget.24809] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 9.3] [Reference Citation Analysis]
43 Gold B, Cankovic M, Furtado LV, Meier F, Gocke CD. Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? J Mol Diagn. 2015;17:209-224. [PMID: 25908243 DOI: 10.1016/j.jmoldx.2015.02.001] [Cited by in Crossref: 121] [Cited by in F6Publishing: 100] [Article Influence: 24.2] [Reference Citation Analysis]
44 Imamura T, Komatsu S, Ichikawa D, Kawaguchi T, Miyamae M, Okajima W, Ohashi T, Arita T, Konishi H, Shiozaki A, Morimura R, Ikoma H, Okamoto K, Otsuji E. Liquid biopsy in patients with pancreatic cancer: Circulating tumor cells and cell-free nucleic acids. World J Gastroenterol. 2016;22:5627-5641. [PMID: 27433079 DOI: 10.3748/wjg.v22.i25.5627] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 37] [Article Influence: 10.3] [Reference Citation Analysis]
45 Béchade D. [Strategies for screening for pancreatic adenocarcinoma in high-risk patients: the place of endoscopic ultrasound]. Presse Med 2011;40:230-8. [PMID: 21211938 DOI: 10.1016/j.lpm.2010.11.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
46 Wei Z, Wang W, Shu Z, Zhou X, Zhang Y. Correlation Between Circulating Tumor DNA Levels and Response to Tyrosine Kinase Inhibitors (TKI) Treatment in Non-Small Cell Lung Cancer. Med Sci Monit 2017;23:3627-34. [PMID: 28742791 DOI: 10.12659/msm.902265] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
47 Däbritz J, Hänfler J, Preston R, Stieler J, Oettle H. Detection of Ki-ras mutations in tissue and plasma samples of patients with pancreatic cancer using PNA-mediated PCR clamping and hybridisation probes. Br J Cancer 2005;92:405-12. [PMID: 15655549 DOI: 10.1038/sj.bjc.6602319] [Cited by in Crossref: 64] [Cited by in F6Publishing: 53] [Article Influence: 4.0] [Reference Citation Analysis]
48 Chen I, Raymond VM, Geis JA, Collisson EA, Jensen BV, Hermann KL, Erlander MG, Tempero M, Johansen JS. Ultrasensitive plasma ctDNA KRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma. Oncotarget 2017;8:97769-86. [PMID: 29228650 DOI: 10.18632/oncotarget.22080] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
49 Liao WC, Wu MS, Wang HP, Tien YW, Lin JT. Serum heat shock protein 27 is increased in chronic pancreatitis and pancreatic carcinoma. Pancreas 2009;38:422-6. [PMID: 19214136 DOI: 10.1097/MPA.0b013e318198281d] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
50 Del Re M, Vivaldi C, Rofi E, Vasile E, Miccoli M, Caparello C, d'Arienzo PD, Fornaro L, Falcone A, Danesi R. Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer. Sci Rep 2017;7:7931. [PMID: 28801547 DOI: 10.1038/s41598-017-08297-z] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 8.5] [Reference Citation Analysis]
51 Jaworski JJ, Morgan RD, Sivakumar S. Circulating Cell-Free Tumour DNA for Early Detection of Pancreatic Cancer. Cancers (Basel) 2020;12:E3704. [PMID: 33317202 DOI: 10.3390/cancers12123704] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
52 Rofi E, Vivaldi C, Del Re M, Arrigoni E, Crucitta S, Funel N, Fogli S, Vasile E, Musettini G, Fornaro L, Falcone A, Danesi R. The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer. Pharmacogenomics 2019;20:49-68. [PMID: 30520336 DOI: 10.2217/pgs-2018-0149] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
53 Parker LA, Lumbreras B, Lopez T, Hernández-Aguado I, Porta M. How useful is it clinically to analyse the K-ras mutational status for the diagnosis of exocrine pancreatic cancer? A systematic review and meta-analysis. Eur J Clin Invest 2011;41:793-805. [PMID: 21391995 DOI: 10.1111/j.1365-2362.2011.02495.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
54 Heredia-Soto V, Rodríguez-Salas N, Feliu J. Liquid Biopsy in Pancreatic Cancer: Are We Ready to Apply It in the Clinical Practice? Cancers (Basel) 2021;13:1986. [PMID: 33924143 DOI: 10.3390/cancers13081986] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
55 Jiao L, Zhu J, Hassan MM, Evans DB, Abbruzzese JL, Li D. K-ras mutation and p16 and preproenkephalin promoter hypermethylation in plasma DNA of pancreatic cancer patients: in relation to cigarette smoking. Pancreas 2007;34:55-62. [PMID: 17198183 DOI: 10.1097/01.mpa.0000246665.68869.d4] [Cited by in Crossref: 65] [Cited by in F6Publishing: 53] [Article Influence: 4.6] [Reference Citation Analysis]
56 Clarke DL, Clarke BA, Thomson SR, Garden OJ, Lazarus NG. The role of preoperative biopsy in pancreatic cancer. HPB (Oxford). 2004;6:144-153. [PMID: 18333068 DOI: 10.1080/13651820410030862] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
57 Li S, Zhang G, Li X, Li X, Chen X, Xu Y, Ren H. Role of the preoperative circulating tumor DNA KRAS mutation in patients with resectable pancreatic cancer. Pharmacogenomics 2021;22:657-67. [PMID: 34120460 DOI: 10.2217/pgs-2020-0183] [Reference Citation Analysis]
58 Dhayat SA, Yang Z. Impact of circulating tumor DNA in hepatocellular and pancreatic carcinomas. J Cancer Res Clin Oncol 2020;146:1625-45. [PMID: 32338295 DOI: 10.1007/s00432-020-03219-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
59 Liu S, Chen G, Zhao Y, Wu W, Zhang T. Diagnostic accuracy of K-ras mutation for pancreatic carcinoma: a meta-analysis. Hepatobiliary & Pancreatic Diseases International 2013;12:458-64. [DOI: 10.1016/s1499-3872(13)60073-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
60 Luchini C, Veronese N, Nottegar A, Cappelletti V, Daidone MG, Smith L, Parris C, Brosens LAA, Caruso MG, Cheng L, Wolfgang CL, Wood LD, Milella M, Salvia R, Scarpa A. Liquid Biopsy as Surrogate for Tissue for Molecular Profiling in Pancreatic Cancer: A Meta-Analysis Towards Precision Medicine. Cancers (Basel) 2019;11:E1152. [PMID: 31405192 DOI: 10.3390/cancers11081152] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
61 Riva F, Dronov OI, Khomenko DI, Huguet F, Louvet C, Mariani P, Stern MH, Lantz O, Proudhon C, Pierga JY. Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer. Mol Oncol. 2016;10:481-493. [PMID: 26856794 DOI: 10.1016/j.molonc.2016.01.006] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 9.6] [Reference Citation Analysis]
62 Ollar RA, Cooperman AM, Wayne ME, Barrecchia JF, Sonpal N, Duddempudi S, Kasmin FE. A colorimetric method for detection of K-ras codon 12 point mutations in DNA extracted from tissue and peripheral blood in pancreatic disorders. Biochem Genet 2010;48:577-89. [PMID: 20383741 DOI: 10.1007/s10528-010-9340-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
63 Makohon-Moore A, Iacobuzio-Donahue CA. Pancreatic cancer biology and genetics from an evolutionary perspective. Nat Rev Cancer. 2016;16:553-565. [PMID: 27444064 DOI: 10.1038/nrc.2016.66] [Cited by in Crossref: 183] [Cited by in F6Publishing: 159] [Article Influence: 36.6] [Reference Citation Analysis]
64 Kaczor-Urbanowicz KE, Cheng J, King JC, Sedarat A, Pandol SJ, Farrell JJ, Wong DTW, Kim Y. Reviews on Current Liquid Biopsy for Detection and Management of Pancreatic Cancers. Pancreas 2020;49:1141-52. [PMID: 33003085 DOI: 10.1097/MPA.0000000000001662] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
65 Agrawal S. Potential prognostic biomarkers in pancreatic juice of resectable pancreatic ductal adenocarcinoma. World J Clin Oncol. 2017;8:255-260. [PMID: 28638795 DOI: 10.5306/wjco.v8.i3.255] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
66 Chen H, Tu H, Meng Z, Chen Z, Wang P, Liu L. K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer. European Journal of Surgical Oncology (EJSO) 2010;36:657-62. [DOI: 10.1016/j.ejso.2010.05.014] [Cited by in Crossref: 81] [Cited by in F6Publishing: 78] [Article Influence: 7.4] [Reference Citation Analysis]
67 Buscail E, Maulat C, Muscari F, Chiche L, Cordelier P, Dabernat S, Alix-Panabières C, Buscail L. Liquid Biopsy Approach for Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2019;11:E852. [PMID: 31248203 DOI: 10.3390/cancers11060852] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
68 Kirkegård J, Mortensen FV, Cronin-fenton D. Chronic Pancreatitis and Pancreatic Cancer Risk: A Systematic Review and Meta-analysis. American Journal of Gastroenterology 2017;112:1366-72. [DOI: 10.1038/ajg.2017.218] [Cited by in Crossref: 141] [Cited by in F6Publishing: 112] [Article Influence: 35.3] [Reference Citation Analysis]
69 Magistrelli P, Neri M, Granone P, Cesario A, Paleari L, Russo P. K-ras mutations in circulating DNA from pancreatic and lung cancers: bridging methodology for a common validation of the molecular diagnosis value. Pancreas. 2008;37:101-102. [PMID: 18580451 DOI: 10.1097/mpa.0b013e31815e72bc] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
70 Gall TMH, Gerrard G, Frampton AE, Castellano L, Ahmad R, Habib N, Spalding D, Pai M, Foroni L, Jiao LR. Can we predict long-term survival in resectable pancreatic ductal adenocarcinoma? Oncotarget 2019;10:696-706. [PMID: 30774772 DOI: 10.18632/oncotarget.26511] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
71 González-Masiá JA, García-Olmo D, García-Olmo DC. Circulating nucleic acids in plasma and serum (CNAPS): applications in oncology. Onco Targets Ther. 2013;6:819-832. [PMID: 23874104 DOI: 10.2147/ott.s44668] [Cited by in Crossref: 9] [Cited by in F6Publishing: 21] [Article Influence: 1.1] [Reference Citation Analysis]
72 Grunvald MW, Jacobson RA, Kuzel TM, Pappas SG, Masood A. Current Status of Circulating Tumor DNA Liquid Biopsy in Pancreatic Cancer. Int J Mol Sci. 2020;21:7651. [PMID: 33081107 DOI: 10.3390/ijms21207651] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
73 Löhr M, Klöppel G, Maisonneuve P, Lowenfels AB, Lüttges J. Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis. Neoplasia 2005;7:17-23. [PMID: 15720814 DOI: 10.1593/neo.04445] [Cited by in Crossref: 209] [Cited by in F6Publishing: 184] [Article Influence: 13.1] [Reference Citation Analysis]
74 Lu L, Bi J, Bao L. Genetic profiling of cancer with circulating tumor DNA analysis. Journal of Genetics and Genomics 2018;45:79-85. [DOI: 10.1016/j.jgg.2017.11.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
75 Wang M, Block TM, Steel L, Brenner DE, Su Y. Preferential Isolation of Fragmented DNA Enhances the Detection of Circulating Mutated k-ras DNA. Clinical Chemistry 2004;50:211-3. [DOI: 10.1373/clinchem.2003.026914] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
76 Abdallah R, Taly V, Zhao S, Pietrasz D, Bachet JB, Basile D, Mas L, Zaanan A, Laurent-Puig P, Taieb J. Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up: A systematic review. Cancer Treat Rev 2020;87:102028. [PMID: 32485509 DOI: 10.1016/j.ctrv.2020.102028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
77 Tajima Y, Kuroki T, Tsutsumi R, Isomoto I, Uetani M, Kanematsu T. Pancreatic carcinoma coexisting with chronic pancreatitis versus tumor-forming pancreatitis: diagnostic utility of the time-signal intensity curve from dynamic contrast-enhanced MR imaging. World J Gastroenterol 2007;13:858-65. [PMID: 17352014 DOI: 10.3748/wjg.v13.i6.858] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 35] [Article Influence: 2.9] [Reference Citation Analysis]
78 Cervena K, Vodicka P, Vymetalkova V. Diagnostic and prognostic impact of cell-free DNA in human cancers: Systematic review. Mutation Research/Reviews in Mutation Research 2019;781:100-29. [DOI: 10.1016/j.mrrev.2019.05.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
79 Allenson K, Castillo J, San Lucas FA, Scelo G, Kim DU, Bernard V, Davis G, Kumar T, Katz M, Overman MJ, Foretova L, Fabianova E, Holcatova I, Janout V, Meric-Bernstam F, Gascoyne P, Wistuba I, Varadhachary G, Brennan P, Hanash S, Li D, Maitra A, Alvarez H. High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients. Ann Oncol 2017;28:741-7. [PMID: 28104621 DOI: 10.1093/annonc/mdx004] [Cited by in Crossref: 188] [Cited by in F6Publishing: 177] [Article Influence: 47.0] [Reference Citation Analysis]
80 Tuveson D, Hingorani S. Ductal Pancreatic Cancer in Humans and Mice. Cold Spring Harbor Symposia on Quantitative Biology 2005;70:65-72. [DOI: 10.1101/sqb.2005.70.040] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 3.6] [Reference Citation Analysis]
81 Khunger M, Kumar U, Roy HK, Tiwari AK. Dysplasia and cancer screening in 21st century. APMIS 2014;122:674-82. [DOI: 10.1111/apm.12283] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
82 Vietsch EE, van Eijck CH, Wellstein A. Circulating DNA and Micro-RNA in Patients with Pancreatic Cancer. Pancreat Disord Ther. 2015;5. [PMID: 26161297 DOI: 10.4172/2165-7092.1000156] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
83 Duffy JP, Reber HA. Pancreatic neoplasms: . Current Opinion in Gastroenterology 2003;19:458-66. [DOI: 10.1097/00001574-200309000-00004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]